(Q34540664)

2 August 2017

1 reference

title

Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457738&resulttype=core&format=json

alpha-1-antitrypsin deficiency

13 May 2020

main subject

1 reference

1

0 references

Helle Krogh Johansen

series ordinal

2

object named as

Helle Krogh Johansen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457738&resulttype=core&format=json

13 May 2020

1

Peter C Gøtzsche

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457738&resulttype=core&format=json

13 May 2020

publication date

20 September 2016

1 reference

Cochrane Database of Systematic Reviews

2 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457738&resulttype=core&format=json

13 May 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457738&resulttype=core&format=json

13 May 2020

page(s)

CD007851

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457738&resulttype=core&format=json

Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.

13 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007851.PUB3

A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007851.PUB3

Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007851.PUB3

Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007851.PUB3

Minimizing the three stages of publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007851.PUB3

Decline in pulmonary function in patients with alpha 1-antitrypsin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007851.PUB3

Beware of surrogate outcome measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007851.PUB3

Believability of relative risks and odds ratios in abstracts: cross sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007851.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007851.PUB3

Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007851.PUB3

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007851.PUB3

Neonatal screening for alpha1-antitrypsin deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007851.PUB3

Alpha-1 proteinase inhibitor (a1PI) for preventing chronic lung disease in preterm infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007851.PUB3

Clinical practice. Alpha1-antitrypsin deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007851.PUB3

Therapeutic efficacy of α-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007851.PUB3

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007851.PUB3

Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007851.PUB3

Liver Disease in Alpha1-Antitrypsin Deficiency Detected by Screening of 200,000 Infants

21 January 2018

1 reference

12 December 2020

Constraints on publication rights in industry-initiated clinical trials

1 reference

12 December 2020

Augmentation therapy in alpha-1 antitrypsin deficiency

1 reference

12 December 2020

Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis

1 reference

12 December 2020

alpha 1-antitrypsin deficiency in early childhood

1 reference

12 December 2020

Natural History and Life Expectancy in Severe Alpha1-Antitrypsin Deficiency, Pi Z

1 reference

12 December 2020

Natural history of alpha-1-protease inhibitor deficiency

1 reference

12 December 2020

10.1002/14651858.CD007851.PUB3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457738&resulttype=core&format=json

release_h2p73ai4ebfp5fsa5sdyuc45xq

13 May 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/h2p73ai4ebfp5fsa5sdyuc45xq

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457738&resulttype=core&format=json

13 May 2020

1 reference